Article Text

Download PDFPDF

Emergency care
Thrombolysis with alteplase 3–4.5 hours after acute ischaemic stroke: trial reanalysis adjusted for baseline imbalances
  1. Brian Scott Alper1,2,
  2. Gary Foster3,4,
  3. Lehana Thabane3,4,
  4. Alex Rae-Grant5,
  5. Meghan Malone-Moses2,
  6. Eric Manheimer2
  1. 1Medical Knowledge Office, EBSCO Information Services, Ipswich, Massachusetts, USA
  2. 2Innovations and Evidence-Based Medicine Development, EBSCO Health, Ipswich, Massachusetts, USA
  3. 3Biostatistics, St Joseph’s Healthcare, Hamilton, Ontario, Canada
  4. 4Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada
  5. 5DynaMed, EBSCO Health, Ipswich, Massachusetts, USA
  1. Correspondence to Dr Brian Scott Alper, Medical Knowledge Office, EBSCO Information Services, Ipswich, MA 01938, USA; balper{at}ebsco.com

Abstract

Objectives Alteplase is commonly recommended for acute ischaemic stroke within 4.5 hours after stroke onset. The Third European Cooperative Acute Stroke Study (ECASS III) is the only trial reporting statistically significant efficacy for clinical outcomes for alteplase use 3–4.5 hours after stroke onset. However, baseline imbalances in history of prior stroke and stroke severity score may confound this apparent finding of efficacy. We reanalysed the ECASS III trial data adjusting for baseline imbalances to determine the robustness or sensitivity of the efficacy estimates.

Design Reanalysis of randomised placebo-controlled trial. We obtained access to the ECASS III trial data and replicated the previously reported analyses to confirm our understanding of the data. We adjusted for baseline imbalances using multivariable analyses and stratified analyses and performed sensitivity analysis for missing data.

Setting Emergency care.

Participants 821 adults with acute ischaemic stroke who could be treated 3–4.5 hours after symptom onset.

Interventions Intravenous alteplase (0.9 mg/kg of body weight) or placebo.

Main outcome measures The original primary efficacy outcome was modified Rankin Scale (mRS) score 0 or 1 (ie, being alive without any disability) and the original secondary efficacy outcome was a global outcome based on a composite of functional end points, both at 90 days. Adjusted analyses were only reported for the primary efficacy outcome and the original study protocol did not specify methods for adjusted analyses. Our adjusted reanalysis included these outcomes, symptom-free status (mRS 0), dependence-free status (mRS 0–2), mortality (mRS 6) and change across the mRS 0–6 spectrum at 90 days; and mortality and symptomatic intracranial haemorrhage at 7 days.

Results We replicated previously reported unadjusted analyses but discovered they were based on a modified interpretation of the National Institutes of Health Stroke Scale (NIHSS) score. The secondary efficacy outcome was no longer significant using the original NIHSS score. Previously reported adjusted analyses could only be replicated with significant effects for the primary efficacy outcome by using statistical approaches not reported in the trial protocol or statistical analysis plan. In analyses adjusting for baseline imbalances, all efficacy outcomes were not significant, but increases in symptomatic intracranial haemorrhage remained significant.

Conclusions Reanalysis of the ECASS III trial data with multiple approaches adjusting for baseline imbalances does not support any significant benefits and continues to support harms for the use of alteplase 3–4.5 hours after stroke onset. Clinicians, patients and policymakers should reconsider interpretations and decisions regarding management of acute ischaemic stroke that were based on ECASS III results.

Trial registration number NCT00153036.

  • stroke
  • emergency medicine
http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Twitter @BrianAlperMD

  • Contributors BSA, MMM and EM were part of the original team which published a call for independent analysis of the trial data for alteplase. BSA, LT, ARG, MMM and EM contributed to the protocol for ECASS III trial reanalysis. BSA negotiated the Data Sharing Agreement. GF conducted the statistical analysis. LT supervised the statistical analysis. All authors edited the manuscript. BSA is the guarantor of the study.

  • Funding GF and LT were supported in part by a charitable contribution from EBSCO Information Services.

  • Disclaimer EBSCO Information Services had no role in the design, conduct, reporting or decision to publish for this research.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement Data may be obtained from a third party and are not publicly available. The authors are unable to share the data as it was obtained through a Data Sharing Agreement with the study sponsor through ClinicalStudyDataRequest.com.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.